Gilead Expands HIV PrEP Access via PAHO Partnership to 3M+ by 2028

Gilead Sciences Inc. has partnered with the Pan American Health Organization (PAHO) to bolster HIV prevention efforts in Latin America and the Caribbean, extending access to lenacapavir—a twice-yearly pre-exposure prophylaxis (PrEP) drug—to an additional 1 million people by 2028, raising total coverage to 3 million. The agreement, announced in September 2026, builds on PAHO’s regional procurement and distribution capabilities through its Revolving Funds, ensuring faster adoption of PrEP in countries where new HIV infections rose by 13% between 2010 and 2024. While Gilead already provides lenacapavir under voluntary licensing agreements in 14 countries outside its existing scope, this collaboration targets 14 additional nations in the region, including Brazil, Chile, and Venezuela, alongside 10 sub-Saharan African countries where the drug is already available. The initiative aligns with broader public health goals, as Dr. Jarbas Barbosa, PAHO Director, emphasized: ‘The Americas today have increasingly effective tools to prevent HIV, but these innovations will have an impact only if they reach the people who need them.’ Gilead’s Chief Commercial & Corporate Affairs Officer, Johanna Mercier, underscored the partnership’s focus on accelerating scientific innovation into accessible healthcare, noting that local production discussions with Brazil’s Ministry of Health may further enhance regional supply chains.